Hansoh Pharma (翰森制药) IPO: Inebilizumab License-In from Viela Bio a Symbolic Deal
Just ahead of the launch of Hansoh Pharma's book building for its USD 1bn IPO, news reported today that Hansoh inked a license-in agreement with...
805 Views
China A-Shares: The 3rd Wave
This report looks at A-Share positioning among GEM, Asia-Ex Japan and Global funds. It serves to highlight the continued growth in both the size...
613 Views
Hansoh Pharma (翰森制药) IPO: Thoughts on Valuation
Hansoh Pharma has started pre-marketing its IPO to raise USD 1bn in its IPO. In our previous insights, we covered the company's major products and...
735 Views
Hansoh Pharma (翰森制药) IPO: New Numbers, Pre-IPO Dividend and Boyu Investment (Part 3)
Hansoh Pharma re-filed prospectus in April and is targeting a listing by summer. In our previous insight, we covered the company's major products...
804 Views
Keytruda Approved for Lung Cancer Treatment in China - A Review of PD-1 Battle Field
Anti-PD-1 monoclonal antibody (mAb) is a hotly contested immunotherapy area in China, with seven companies working on clinical trials covering...
643 Views